Global Liver Cancer Therapeutics Market
According to the report " Liver Cancer Therapeutics Market ", published by Market Data Forecast, the global market is projected to reach USD 884.14 million by 2021, at a CAGR of 9.1 % from 2016 to 2021.
Treating cancer is still not easy because disease symptoms generally appear in the late stage of the disease, resulting in a low diagnosis rate that in turn disturbs the patient volume available for treatment. Studies on liver cancer therapeutics illustrate that the prevalence of liver cancer is greater in men than in women and is generally seen in people over the age of 50. Treatment is based on tumour size, location, and overall health.
Increasing number of liver cancer cases all over the globe involves huge amount of drugs for the treatment or prevention of liver cancer and tumours. Further, growing healthcare expenditure and increasing government initiatives are also augmenting the growth of this market. Additionally, high unmet necessities for the treatment of liver cancer also supports in market growth.
The Global Liver Cancer Therapeutics Market is segmented by Type, Therapeutics, End- Users and region.
1) By Type:
� � �
Primary Secondary Benign Liver Growths
2) By Therapeutics:
� � � �
Hepatocellular Carcinoma Cholangio Carcinoma Hepatoblastoma Targeted Therapy
3) By End-Users:
� �
Pediatrics Adults
4) By Geography:
� � � � �
North America Europe Asia-Pacific Latin America Middle-East and Africa
Some of the key contributors in the industry include Alnylam Pharmaceuticals Inc., ImClone Systems Inc., Onyx Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., ArQule Inc.,
+ 1 888-702-9626 | www. marketdataforecast. com | contact @ marketdataforecast. com